10-Q: Immunocore Reports Q1 2026 Results, Revenue Up 13.6%

Immunocore Holdings plc announced its first-quarter 2026 financial results, showcasing a 13.6% increase in total revenue driven by strong sales of its lead therapy, KIMMTRAK.

Summary

• Immunocore Holdings plc reported first-quarter 2026 results, with total revenue reaching $106.7 million, a 13.6% increase compared to $93.9 million in the same period of 2025.
• The company's lead product, KIMMTRAK, generated $106.7 million in net revenue from therapy sales, primarily in the United States ($67.4 million) and Europe ($34.4 million).
• Research and development expenses increased by 8.2% to $61.1 million, largely due to higher costs for PRAME programs and increased employee-related costs.
• Selling, general, and administrative expenses decreased by 5.7% to $37.9 million.
• Net income for the quarter was $13.0 million, a significant increase from $5.0 million in the first quarter of 2025.
• The company ended the quarter with $452.7 million in cash and cash equivalents and $392.2 million in marketable securities, indicating a strong liquidity position.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by strong revenue growth and improved net income, alongside encouraging clinical data for KIMMTRAK. The company's solid liquidity position is also a key positive, though the ongoing need for future funding and accumulated deficit are noted.

Positives

• Total revenue increased by 13.6% to $106.7 million for the three months ended March 31, 2026, compared to $93.9 million for the same period in 2025.
• Revenue from the sale of therapies, primarily KIMMTRAK, saw a 13.6% increase, driven by strong sales volume in the United States and Europe, and global country expansion.
• Net income significantly increased to $13.0 million for the first quarter of 2026, up from $5.0 million in the first quarter of 2025.
• The company maintains a strong liquidity position with $452.7 million in cash and cash equivalents and $392.2 million in marketable securities as of March 31, 2026.
• The five-year overall survival data from the pivotal Phase 3 trial for KIMMTRAK in unresectable or metastatic uveal melanoma (mUM) showed a doubling of the likelihood of being alive at five years (16% vs. 8%).
• The company presented positive data on KIMMTRAK's durability of benefit and observed OS benefit regardless of prognostic factors or tumor location.

Negatives

• Research and development expenses increased by 8.2% to $61.1 million, driven by higher costs for PRAME programs and increased employee-related costs.
• While net income increased, the company still has an accumulated deficit of $818.3 million as of March 31, 2026.
• The company expects to continue to incur significant operating losses and increasing expenses in the foreseeable future.
• A global recall for one batch of KIMMTRAK was initiated in June 2025 due to an unexpected result in routine stability testing, though no material impact is currently expected.

Risks

• The company's ability to generate higher levels of revenue from other marketed products depends on the successful development and regulatory approval of its product candidates.
• The company may need additional funding to support its continued operations and pursue its clinical development and growth strategy, and may be unable to raise such funds on favorable terms.
• The company faces risks related to the initiation, timing, progress, and results of its ongoing and planned clinical trials, including potential delays or disruptions.
• The company's ability to obtain and maintain regulatory approval for KIMMTRAK in additional indications and jurisdictions is subject to uncertainty.
• The company is subject to risks associated with the commercialization and marketing of KIMMTRAK, including market acceptance, reimbursement, and pricing.
• The company's financial performance and ability to manage anticipated growth are subject to various risks, including macroeconomic conditions, supply chain disruptions, and fluctuating exchange rates.
• The company faces competition from current and future competitors in the industry.
• The company's ability to obtain, maintain, and enforce intellectual property protection for its products and product candidates is crucial.

Future Outlook

Immunocore expects to continue incurring significant operating losses and increasing expenses as it advances its product candidates through development and commercialization. The company anticipates increased R&D expenses to support ongoing and future clinical studies and regulatory approvals. Future funding will likely come from equity or debt offerings, or collaborations, as the company aims to support its long-term clinical development and operational needs.

Management Comments

• "We presented the five-year overall survival (OS) from our pivotal Phase 3 trial with KIMMTRAK in unresectable or mUM... These results also represent the longest follow-up reported for any T cell engager in a solid tumor."
• "In the Phase 3 trial, KIMMTRAK doubled the likelihood of being alive at five years, with an OS for KIMMTRAK of 16% versus 8% in the control arm."
• "We believe that these tumor types have large addressable patient populations and significant unmet need."
• "Despite the net income result for the three months ended March 31, 2026, we expect to continue to incur significant and increasing expenses and to incur operating losses for the foreseeable future."

Industry Context

StockSavvy.ai notes that Immunocore's performance in Q1 2026 reflects the ongoing growth trajectory for targeted immunotherapies in oncology, particularly in rare and difficult-to-treat cancers like uveal melanoma. The company's ability to generate increasing revenue from KIMMTRAK, coupled with positive long-term survival data, positions it favorably within the competitive biotech landscape. However, the substantial R&D investment highlights the inherent costs and risks associated with advancing a pipeline of novel therapies.

Comparison to Industry Standards

• The five-year overall survival rate of 16% for KIMMTRAK in unresectable or metastatic uveal melanoma (mUM) significantly outperforms the historical survival rate of less than 5% for this disease.
• The median overall survival of 21.6 months on KIMMTRAK versus 16.9 months on investigator's choice (IC) in the Phase 3 trial demonstrates a competitive advantage over existing treatment options.
• The reported hazard ratio of 0.67 for overall survival with KIMMTRAK indicates a substantial reduction in the risk of death compared to the control arm, a key metric for efficacy in oncology trials.
• The company's revenue growth of 13.6% in Q1 2026 is a solid performance for a commercial-stage biotech company, especially considering the specialized nature of its lead product.

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Stakeholder Impact

• Shareholders: Positive impact from increased revenue and net income, and encouraging clinical data for KIMMTRAK. Potential dilution if future capital raises occur.
• Employees: Continued investment in R&D and commercial expansion may lead to increased headcount and opportunities, but also ongoing R&D expenses.
• Customers/Patients: Continued access to KIMMTRAK for metastatic uveal melanoma and potential future therapies for other indications.
• Creditors: The company has significant debt from convertible senior notes, but interest payments are being met, and the company has sufficient liquidity.

Next Steps

• Present two posters at the 2026 American Society of Clinical Oncology Meeting: 'Phase 1 evaluation of the PRAME-targeted ImmTAC brenetafusp in advanced melanoma' and 'Effect of IL7 on ImmTAC-mediated killing by T cells in vitro and T-cell fitness in patients'.
• Continue to launch and seek approvals for KIMMTRAK in additional territories.
• Advance clinical and preclinical programs for tebentafusp, brenetafusp, IMC-P115C, IMC-R117C, IMC-M113V, IMC-S118AI, and IMC-U120AI.
• Continue to build a sustainable pipeline of new product candidates using the ImmTAX platform.
• Continue to execute sales and marketing strategy for KIMMTRAK globally.
• Explore additional financing opportunities when market terms are favorable.

Key Dates

Recommendation

The company demonstrates solid revenue growth and improved profitability, supported by positive clinical data for its lead product, KIMMTRAK. However, the significant accumulated deficit and the stated expectation of continued operating losses and future financing needs warrant a cautious approach. While the company is progressing, the inherent risks in drug development and the need for future capital suggest a 'hold' recommendation until further clarity on long-term profitability and pipeline success is achieved.

Keywords

Immunocore, 10-Q, KIMMTRAK, uveal melanoma, oncology, biotechnology, financial results, revenue, R&D, clinical trials, ImmTAX platform, tebentafusp, brenetafusp